

A Response to the Restriction Requirement:**A. Status of the Claims**

Claims 1-13 were pending at the time of the Restriction Requirement. Claims 1-6, 9, and 11-13 have been cancelled without prejudice or disclaimer. Claim 7, 8, and 10 have been amended and claims 14-30 have been added to correspond to the election of the Group I invention that is made below by Applicants. In view of the fact that the amendment relates only to corresponding to the election of the Group I invention, it does not, in any way, affect the scope of the claim or range of equivalents to which the elements in the claim are entitled. Claims 7, 8, 10, and 14-30, therefore, are currently pending.

B. Response to Restriction Requirement

In response to the Restriction Requirement, Applicants elect, without traverse, to prosecute the Group II invention, as exemplified by claims 7-10, classified in class 514, subclass 1. Claims drawn to the inventions of Groups I and III-V, claims 1-6 and 11-13, have been cancelled from the present case without prejudice or disclaimer.

The Restriction Requirement also requests Applicants to elect for further prosecution a polypeptide selected from SCN1A, SCN2A, and SCN3A. In response, Applicants elect to prosecute claims directed towards the SCN1A polypeptide.

Applicants reserve the right to prosecute claims directed to the non-elected inventions in continuing applications.

C. Response to the Sequence Listing Issues

At the request of the Examiner, Applicants have also included a revised sequence listing (including a computer readable form) and the corresponding papers pursuant to 37 C.F.R. §§ 1.821-1.825. Applicants have included with each sequence listing, the identification of the changes that were made to the original sequence listing.

D. Conclusion

Applicants believes this to be a full and complete response to the Restriction Requirement dated March 25, 2003. Applicants respectfully request favorable consideration of this case in view of the above comments and amendments. Should the Examiner have any questions, comments, or suggestions relating to this case, the Examiner is invited to contact the undersigned Applicant's representative at (512) 536-3020.